Developing Countries' Vaccine Manufacturers' Network International

Improving vaccination for all people



Developing Countries Vaccine Manufacturers Network

CONFIDENTIAL - DRAFT - FOR INTERNAL USE ONLY

Mission: our purpose and mandate



 To protect all people against known and emerging infectious diseases, by **improving** the availability of high-quality vaccines globally. CONFIDENTIAL - DRAFT - FOR INTERNAL

DCVMN International


- It is a <u>voluntary</u>, <u>non-governmental</u>, <u>non-partisan</u>, <u>not-for-profit</u>, <u>public health driven</u> alliance of vaccine manufacturers, research and policy organizations from all over the world.
- Operates based on principles of international scientific, technical and economic cooperation.

Developing Countries Economies



https://www.un.org/development/desa/dpad/wp-content/uploads/sites/45/WESP2019_BOOK-web.pdf


DCVMN 2019: 44 manufacturers from 14 countries/territories



number of birth cohorts 2015 regionally are indicated in black (x1000) http://www.who.int/immunization/monitoring_surveillance/data/en/


Our Challenge : vaccination to all people Our Chance: partnerships

The developing world needs more vaccines




Global Vaccination Coverage at Its Highest

Coverage with three doses of diphtheria-, tetanus-, and pertussiscontaining vaccines (DTP3), by country income levels, 1980–2015



https://www.gatesnotes.com/2017-Annual-Letter

DCVMN Contributions to the Global Vaccination Landscape



Initiatives 2019-2021 to Support DCVMs

Developing Countries Vaccine Manufacturers Network

BILL& MELINDA GATES foundation

Imperial College London


Our main 3 goals are to:

- A) build **technical capabilities** and strengthen capacity of MFs to produce and deliver quality vaccines across the long-term,
- B) proactively engage DCVMN members on priority issues shaping the broader landscape (e.g., **regulatory knowledge**, **supply chain**, etc.) and
- C) establish more systematic & proactive dialogue with international bodies to shape DCVM issues.

Interviews and extensive discussions were conducted with members and 6 initiatives were **recommended**:

- 1. Training: Expand current QMS programs to include training on GMP, GCP, GLP, GDP, PV, etc.
- 2. Best-practice sharing: foster peer to peer communication through expert working groups
- 3. Advance regulatory convergence: support efforts to new approaches on a regional basis
- 4. Increase access to international expert consultants for needed ad hoc support
- 5. Engage MFs on new technology adoption through AGM
- 6. Support for **pharmacovigilance** (PV) projects **to enhance vaccines safety** monitoring


1. Teach to Reach




Source: National Training Laboratories, Bethel, Maine

1. Training: Expand current QMS programs to include training on GMP, GCP, GLP, GDP, PV, and other issues

Teach to reach



E-Learning resources on DCVMN website



Immersive learning: investing in people to create innovative mindset & enablement prior to "hands on"

VR hands on training



3 «hands-on» main scenarios where VR training can impact operational capacity:

- 1. Equipment operation
- 2. Emergency management
- 3. Laboratory (testing/formulation)



https://drive.google.com/file/d/1xeF3Lm8rNgeU0YFH6hE3NExnDOIkxvxF/view

Training Chain: relay training



Imperial College London

- Focus on QC assays to improve technology /methodology, reducing risks and inspections
- Support QC Team training in a expert QC lab (NIBSC/ISS/ etc.) for new testing assays:
 - One "trainee" at a time (2-4 weeks), on a relay setting to build strong teams (3-5 people). Next trainee comes only when the previous returned and passed on the knowledge
- Enables common understanding of the whole process and team building and 3Rs, and sustainability


2. Expert Networking

- Enhance <u>best-practice sharing</u>, and peer to peer communications through expert working groups and hands-on training, as possible
 - Supply-chain experts working group
 - Vaccine Safety best-practices
 - QC assays & technologies
 - Formulation & filling expertise
 - Etc...

3. Foster dialogue to advance regulatory convergence approaches

Challenges to registrations were identified by an independent expert consultant and discussed with members

- ✓ Create <u>consensus among manufacturers</u> <u>from both DCVMN-IFPMA</u> on key points for dialogue before communicating with NRAs
- ✓ Two papers published, increasing awareness of challenges and solutions
- ✓ Supporting regulatory open discussions at stakeholder meetings, as for example:
 - > AVAREF, ICDRA, ASEAN, PANDHR, CoRE
- Study on changes/variations to improve vaccines' access
- ✓ 3Rs: innovative assays to reduce animal use



https://www.ncbi.nlm.nih.gov/pubmed/29724510



In press



4. Access to International Experts

- DCVMN's Consultants Portal at www.dcvmn.org
- Consultants register themselves in the DCVMN database
 - Centralized pool of expertise
 - Transparency on qualifications
 - Consultants based in 22 countries
 - Declared availability to DCVMN and to Members
 - Not working for other manufacturers and "moonlighting"
- > 100 registered consultants; <u>ca.</u> 50% already "engaged" by DCVMN

2 funding calls – Oct 2018 and Feb 2019 (up to \$50,000) for consultancy support for developing country members of DCVMN. Imperial College London


FVMR Hub awarded \$90,000 to two such members (one manufacturer in China and another in India).

Next call in ~Oct 2019.



Biological E. Limited

Celebrating Life Everyday



- How to ensure calls meet needs of manufacturers
- How to improve the quality of the application
- How to grow enduring partnerships

5. Engage members on innovative technologies adoption




30th October 2018, AGM, Bill Gates: "looking forward to the partnerships we can have over the next decade"


https://www.dcvmn.org/IMG/pdf/bill gates kunming video news.pdf

6. Pharmacovigilance (PV) to improving vaccines safety monitoring

Building Blocks of Efficient Quality Systems for Pharmacovigilance*



Number of DCVMs PQed vaccines over 25 years: DCVMN works



(*Sanofi = 30; GSK = 17; Seqirus = 6; MSD = 4; J&J = 2; Pfizer = 2, among others MFs)

Memberships and Strong Partnerships towards building healthy countries



"Coming together is a beginning; keeping together is progress; working together is success."

Credit: http://www.vibincblog.com/?tag=partnership

3Rs

• Reliable:

 able to be trusted; consistently good in quality or performance: «yes means yes, no means no» attitude

• Responsive:

 responding readily and with interest or enthusiasm: «answer to queries, emails, reports, etc.» attitude

Responsible:

- be answerable for one's actions; having control over or accountable for something, as part of one's job/ role.
- "Yes, I do", "yes, I can", "yes, I will" attitude

DCVMN Collaborating organizations and Partners





Individually we are one drop, together we are an ocean Ryunosuke Satoro

DCVMN International

www.dcvmn.org